The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.
The FDA has approved enflonsia, a fixed-dose monoclonal antibody, for preventing RSV lower respiratory tract disease in infants during their first season.
A study of 32,960 hospitalizations finds 10.9% of patients with RSV experienced acute cardiovascular events, with significantly higher adjusted odds than boosted and unboosted COVID-19 cases.
Investigation reveals tobacco-funded studies appear in top medical journals despite industry bans, as companies invest billions in pharmaceutical subsidiaries.
A large European study found that early-life dog exposure may reduce the genetic risk for atopic eczema, with lab results confirming a biological mechanism involving immune signaling in skin cells.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
In a UK-wide analysis of nearly 2 million patients, researchers found that “a fifth of patients receiving corticosteroids accounted for over 80% of oral and inhaled corticosteroid prescribing,” highlighting concentrated use and variable treatment persistence across formulations.
A new clinical trial found that adding mepolizumab to standard inhaled therapy significantly reduced moderate or severe COPD exacerbations in patients with high eosinophil counts, with a 21% lower annual rate and longer time to first flare.
A study of over 500,000 patients found that using inhaled corticosteroids for more than 2 years in COPD significantly increased the risk of diabetes, pneumonia, fractures, cataracts, and osteoporosis.